Aktiesnakken — Juli 2010
-
KAn det virkelig være rigtigt at det er så billigt med udgiftsloftet
-
hvorfor assuming 50/50 split?
-
det kommer nye studier
-
likely spending will increase
-
men cappet gælder hele det nuværende planlagte program i onkologi
-
det må være GSK der suger de omkostninger op
-
nu lidt på royalties
-
Autoimmune Royalty er ændret
-
men det er de originale dobbelt digit i onkology
-
den går i 80 næste uge
-
jo måske
-
jeg tror nordea blev meget lune
-
very good deal for both companies
-
Frank et al skal lige hjem og finde en undskyldning for at ændre bias
-
subcut er undervejs
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind